<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02099110</url>
  </required_header>
  <id_info>
    <org_study_id>8835-005</org_study_id>
    <secondary_id>MK-8835-005</secondary_id>
    <secondary_id>B1521019</secondary_id>
    <secondary_id>2013-003698-82</secondary_id>
    <nct_id>NCT02099110</nct_id>
  </id_info>
  <brief_title>Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)</brief_title>
  <official_title>A Phase III, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin Compared With Ertugliflozin Alone and Sitagliptin Alone, in the Treatment of Subjects With T2DM With Inadequate Glycemic Control on Metformin Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study of co-administration of ertugliflozin (MK-8835/PF-04971729) and sitagliptin
      given together or alone along with metformin in participants with Type 2 diabetes mellitus
      (T2DM) and inadequate glycemic control on metformin monotherapy. The primary hypothesis of
      this study is that ertugliflozin 15 mg daily plus sitagliptin 100 mg daily provides greater
      hemoglobin A1C (A1C)-lowering compared with sitagliptin 100 mg daily alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will include a 1-week screening period; an up to 12-week metformin titration/dose
      stabilization period; a 2-week single-blind placebo run-in period; a 52-week (26-week Phase A
      and 26-week Phase B) double-blind treatment period and a post-treatment telephone contact 14
      days after the last dose of study medication.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 22, 2014</start_date>
  <completion_date type="Actual">May 26, 2016</completion_date>
  <primary_completion_date type="Actual">May 26, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in A1C at Week 26: Excluding Rescue Approach</measure>
    <time_frame>Baseline and Week 26</time_frame>
    <description>A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). This change from baseline reflects the Week 26 A1C minus the Week 0 A1C. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Experienced an Adverse Event (AE): Including Rescue Approach</measure>
    <time_frame>Up to 54 weeks</time_frame>
    <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Including rescue approach data analysis included data following the initiation of rescue therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Discontinued Study Treatment Due to an AE: Including Rescue Approach</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Including rescue approach data analysis included data following the initiation of rescue therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Weight at Week 26: Excluding Rescue Approach</measure>
    <time_frame>Baseline and Week 26</time_frame>
    <description>This change from baseline reflects the Week 26 body weight minus the Week 0 body weight. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26 - Excluding Rescue Approach</measure>
    <time_frame>Baseline and Week 26</time_frame>
    <description>Blood glucose was measured on a fasting basis after at least a 10-hour fast. This change from baseline reflects the Week 26 FPG minus the Week 0 FPG. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a Hemoglobin A1C of &lt;7% (&lt;53 mmol/Mol) (Raw Proportions): Excluding Rescue Approach</measure>
    <time_frame>Week 26</time_frame>
    <description>A1C is blood marker used to report average blood glucose levels over a prolonged periods of time and is reported as a percentage (%). Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Static Beta-Cell Sensitivity to Glucose Index at Week 26; Excluding Rescue Approach</measure>
    <time_frame>30 min. before and 0, 15, 30, 60, 90, 120, and 180 minutes following the start of the standard meal at Baseline and Week 26</time_frame>
    <description>Static beta-cell sensitivity to glucose index (SBCSGI) estimates the ratio of insulin secretion (expressed in pmol/min) related to above-basal glucose concentration (expressed in mmol/L * L) following a meal. Blood samples were collected before and after a standard meal and glucose, insulin, and C-peptide levels were analyzed. The C-peptides minimal model was used to estimate the insulin secretion rate (ISR). Analysis included both non-model-based [including insulinogenic index with C-peptide, glucose area under the curve (AUC)/insulin AUC] and model-based [beta cell function and insulin secretion rate at 9 mM glucose] testing. Analysis was performed with non-linear least squares using the Software Architecture Analysis Method (SAAM) II software. SBCSGI was expressed in units of 10^-9 min^-1. Excluding rescue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Sitting Systolic Blood Pressure at Week 26: Excluding Rescue Approach</measure>
    <time_frame>Baseline and Week 26</time_frame>
    <description>This change from baseline reflects the Week 26 systolic blood pressure minus the Week 0 systolic blood pressure. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">1233</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Ertugliflozin 5 mg + sitagliptin 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ertugliflozin 5 mg + sitagliptin 100 mg, oral, once daily for 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ertugliflozin 15 mg + sitagliptin 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ertugliflozin 15 mg + sitagliptin 100 mg, oral, once daily for 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ertugliflozin 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ertugliflozin 5 mg, oral, once daily for 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ertugliflozin 15 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ertugliflozin, oral, once daily for 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin 100 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sitagliptin 100 mg, oral, once daily for 52 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo to Ertugliflozin 5 mg</intervention_name>
    <description>Placebo to ertugliflozin 5 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period</description>
    <arm_group_label>Sitagliptin 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo to Ertugliflozin 10 mg</intervention_name>
    <description>Placebo to ertugliflozin 10 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period</description>
    <arm_group_label>Ertugliflozin 5 mg + sitagliptin 100 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 5 mg</arm_group_label>
    <arm_group_label>Sitagliptin 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo to sitagliptin 100 mg</intervention_name>
    <description>Placebo to sitagliptin 100 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period</description>
    <arm_group_label>Ertugliflozin 5 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 15 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ertugliflozin 5 mg</intervention_name>
    <description>Ertugliflozin 5 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period</description>
    <arm_group_label>Ertugliflozin 5 mg + sitagliptin 100 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 15 mg + sitagliptin 100 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 5 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 15 mg</arm_group_label>
    <other_name>MK-8835</other_name>
    <other_name>PF-04971729</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ertugliflozin 10 mg</intervention_name>
    <description>Ertugliflozin 10 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period</description>
    <arm_group_label>Ertugliflozin 15 mg + sitagliptin 100 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 15 mg</arm_group_label>
    <other_name>MK-8835</other_name>
    <other_name>PF-04971729</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin 100 mg</intervention_name>
    <description>Sitagliptin 100 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period</description>
    <arm_group_label>Ertugliflozin 5 mg + sitagliptin 100 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 15 mg + sitagliptin 100 mg</arm_group_label>
    <arm_group_label>Sitagliptin 100 mg</arm_group_label>
    <other_name>JANUVIA®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin &gt;= 1500 mg/day</intervention_name>
    <description>Metformin &gt;= 1500 mg/day, tablets, oral, for 52 weeks while receiving blinded investigational product during the double-blind treatment period</description>
    <arm_group_label>Ertugliflozin 5 mg + sitagliptin 100 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 15 mg + sitagliptin 100 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 5 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 15 mg</arm_group_label>
    <arm_group_label>Sitagliptin 100 mg</arm_group_label>
    <other_name>Glucophage</other_name>
    <other_name>Glucophage XR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Insulin Glargine Rescue Medication</intervention_name>
    <description>Open-label insulin glargine, subcutaneous injection, as required as a rescue medication; dose determined per the investigator's discretion</description>
    <arm_group_label>Ertugliflozin 5 mg + sitagliptin 100 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 15 mg + sitagliptin 100 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 5 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 15 mg</arm_group_label>
    <arm_group_label>Sitagliptin 100 mg</arm_group_label>
    <other_name>Lantus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glimepiride Rescue Medication</intervention_name>
    <description>Open-label glimepiride tablets, oral, as required as a rescue medication, dose determined per the investigator's discretion</description>
    <arm_group_label>Ertugliflozin 5 mg + sitagliptin 100 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 15 mg + sitagliptin 100 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 5 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 15 mg</arm_group_label>
    <arm_group_label>Sitagliptin 100 mg</arm_group_label>
    <other_name>AMARYL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes mellitus as per American Diabetes Association guidelines

          -  On metformin monotherapy (&gt;=1500 mg/day) for &gt;=8 weeks with a Visit 1/Screening A1C
             &gt;=7.5% and &lt;=11.0% (&gt;=58 mmol/mol and &lt;=97 mmol/mol) OR On metformin monotherapy
             (&gt;=1500 mg/day) for &lt;8 weeks with a Visit 1/Screening A1C &gt;=7.5% and &lt;=11.0% (&gt;=58
             mmol/mol and &lt;=97 mmol/mol) OR On metformin monotherapy &lt;1500 mg/day with a Visit
             1/Screening A1C &gt;=8.0% and &lt;=11.5% (&gt;=64 mmol/mol and &lt;=102 mmol/mol)

          -  Body mass index (BMI) &gt;=18.0 kg/m^2

          -  Male or female not of reproductive potential

          -  Female of reproductive potential who agrees to remain abstinent from heterosexual
             activity or to use 2 acceptable combinations of contraception

        Exclusion Criteria:

          -  History of type 1 diabetes mellitus or ketoacidosis

          -  History of other specific types of diabetes (e.g., genetic syndromes, secondary
             pancreatic diabetes, diabetes due to endocrinopathies, drug- or chemical-induced, and
             post-organ transplant

          -  A known hypersensitivity or intolerance to any sodium glucose co-transporter 2 (SGLT2)
             inhibitor or sitagliptin

          -  Has been treated with any of the following agents within 12 weeks of study start or
             during the pre-randomization period: Insulin of any type (except for short-term use
             [i.e., &lt;=7 days] during concomitant illness or other stress), other injectable
             anti-hyperglycemic agents (e.g., pramlintide, exenatide, liraglutide), pioglitazone or
             rosiglitazone, other SGLT2 inhibitors, alpha glucosidase inhibitors or meglitinides,
             dipeptidyl-peptidase 4 inhibitor (DPP-4 inhibitor), sulfonylureas (SUs), bromocriptine
             (Cycloset™), colesevelam (Welchol™), any other antihyperglycemic agents (AHA) with the
             exception of the protocol-approved agents

          -  Is on a weight-loss program or weight-loss medication or other medication associated
             with weight changes and is not weight stable prior to study start

          -  Has undergone bariatric surgery within the past 12 months or &gt;12 months and is not
             weight stable prior to study start

          -  A history of myocardial infarction, unstable angina, arterial revascularization,
             stroke, transient ischemic attack, or New York Heart Association (NYHA) functional
             class III-IV heart failure within 3 months of study start

          -  Active, obstructive uropathy or indwelling urinary catheter

          -  History of malignancy &lt;=5 years prior to study start, except for adequately treated
             basal cell or squamous cell skin cancer or in situ cervical cancer

          -  A known history of human immunodeficiency virus (HIV)

          -  A blood dyscrasia or any disorder causing hemolysis or unstable red blood cells, or a
             clinically important hematological disorder (e.g. aplastic anemia, myeloproliferative
             or myelodysplastic syndromes, thrombocytopenia)

          -  A medical history of active liver disease (other than non-alcoholic hepatic
             steatosis), including chronic active hepatitis B or C, primary biliary cirrhosis, or
             symptomatic gallbladder disease

          -  Any clinically significant malabsorption condition

          -  Current treatment for hyperthyroidism

          -  On thyroid replacement therapy and not on a stable dose for at least 6 weeks prior
             study start

          -  On a previous clinical study with ertugliflozin

          -  Estimated glomerular filtration rate (eGFR) (using the 4-variable Modification of Diet
             in Renal Disease Study Equation (MDRD) equation) &lt;60 mL/min/1.73 m^2

          -  Serum creatinine &gt;= 1.3 mg/dL (115 µmol/L) for males and &gt;= 1.2 mg/dL (106 µmol/L) for
             females

          -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt;2 times upper
             limit of normal

          -  Hemoglobin &lt;12 g/dL (120 g/L) for males and &lt;11 g/dL (110 g/L) for females.

          -  Participated in other studies involving investigational drug(s) 30 days prior to study
             start

          -  Surgical procedure within 6 weeks prior to study start or major surgery planned during
             the trial

          -  Positive urine pregnancy test

          -  Pregnant or breast-feeding, or planning to conceive during the trial, including 14
             days following the last dose of study medication

          -  Planning to undergo hormonal therapy in preparation for egg donation during the trial,
             including 14 days following the last dose of study medication

          -  Routinely consumes &gt;2 alcoholic drinks per day or &gt;14 alcoholic drinks per week or
             engages in binge drinking

          -  Donated blood or blood products within 6 weeks of study start
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Argentina</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>Czech Republic</country>
    <country>Finland</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>New Zealand</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Thailand</country>
    <country>Ukraine</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Pratley RE, Eldor R, Raji A, Golm G, Huyck SB, Qiu Y, Sunga S, Johnson J, Terra SG, Mancuso JP, Engel SS, Lauring B. Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial. Diabetes Obes Metab. 2018 May;20(5):1111-1120. doi: 10.1111/dom.13194. Epub 2018 Jan 25.</citation>
    <PMID>29266675</PMID>
  </results_reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 25, 2014</study_first_submitted>
  <study_first_submitted_qc>March 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2014</study_first_posted>
  <results_first_submitted>August 10, 2017</results_first_submitted>
  <results_first_submitted_qc>October 2, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">November 1, 2017</results_first_posted>
  <last_update_submitted>January 25, 2018</last_update_submitted>
  <last_update_submitted_qc>January 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The trial was conducted in 21 countries and included 242 trial centers.</recruitment_details>
      <pre_assignment_details>Participants on ≥1500 mg/day of metformin for ≥8 weeks with A1C ≥7.5 and ≤11% at screening could directly enter a 2-week, single-blind, placebo run-in period. Participants who did not meet these criteria, received diet/exercise counseling and metformin titration (as necessary) for ~8 weeks before entering the 2-week, placebo run-in period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ertugliflozin 5 mg</title>
          <description>Ertugliflozin 5 mg, oral, once daily for 52 weeks</description>
        </group>
        <group group_id="P2">
          <title>Ertugliflozin 15 mg</title>
          <description>Ertugliflozin, oral, once daily for 52 weeks</description>
        </group>
        <group group_id="P3">
          <title>Sitagliptin 100 mg</title>
          <description>Sitagliptin 100 mg, oral, once daily for 52 weeks</description>
        </group>
        <group group_id="P4">
          <title>Ertugliflozin 5 mg + Sitagliptin 100 mg</title>
          <description>Ertugliflozin 5 mg + sitagliptin 100 mg, oral, once daily for 52 weeks</description>
        </group>
        <group group_id="P5">
          <title>Ertugliflozin 15 mg + Sitagliptin 100 mg</title>
          <description>Ertugliflozin 15 mg + sitagliptin 100 mg, oral, once daily for 52 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="250"/>
                <participants group_id="P2" count="248"/>
                <participants group_id="P3" count="247"/>
                <participants group_id="P4" count="243"/>
                <participants group_id="P5" count="245"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="250"/>
                <participants group_id="P2" count="248"/>
                <participants group_id="P3" count="247"/>
                <participants group_id="P4" count="243"/>
                <participants group_id="P5" count="244"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="226"/>
                <participants group_id="P2" count="217"/>
                <participants group_id="P3" count="219"/>
                <participants group_id="P4" count="221"/>
                <participants group_id="P5" count="218"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="28"/>
                <participants group_id="P4" count="22"/>
                <participants group_id="P5" count="27"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant moved</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Screen failure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with study drug</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Baseline Analysis Population was the All-Participants-As-Treated population. One participant randomized to the Ertugliflozin 15 mg + Sitagliptin 100 mg arm did not receive study medication.</population>
      <group_list>
        <group group_id="B1">
          <title>Ertugliflozin 5 mg</title>
          <description>Ertugliflozin 5 mg, oral, once daily for 52 weeks</description>
        </group>
        <group group_id="B2">
          <title>Ertugliflozin 15 mg</title>
          <description>Ertugliflozin, oral, once daily for 52 weeks</description>
        </group>
        <group group_id="B3">
          <title>Sitagliptin 100 mg</title>
          <description>Sitagliptin 100 mg, oral, once daily for 52 weeks</description>
        </group>
        <group group_id="B4">
          <title>Ertugliflozin 5 mg + Sitagliptin 100 mg</title>
          <description>Ertugliflozin 5 mg + sitagliptin 100 mg, oral, once daily for 52 weeks</description>
        </group>
        <group group_id="B5">
          <title>Ertugliflozin 15 mg + Sitagliptin 100 mg</title>
          <description>Ertugliflozin 15 mg + sitagliptin 100 mg, oral, once daily for 52 weeks</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="250"/>
            <count group_id="B2" value="248"/>
            <count group_id="B3" value="247"/>
            <count group_id="B4" value="243"/>
            <count group_id="B5" value="244"/>
            <count group_id="B6" value="1232"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="250"/>
                    <count group_id="B2" value="248"/>
                    <count group_id="B3" value="247"/>
                    <count group_id="B4" value="243"/>
                    <count group_id="B5" value="244"/>
                    <count group_id="B6" value="1232"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.1" spread="10.1"/>
                    <measurement group_id="B2" value="55.3" spread="9.5"/>
                    <measurement group_id="B3" value="54.8" spread="10.7"/>
                    <measurement group_id="B4" value="55.2" spread="10.4"/>
                    <measurement group_id="B5" value="55.1" spread="9.8"/>
                    <measurement group_id="B6" value="55.1" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="250"/>
                    <count group_id="B2" value="248"/>
                    <count group_id="B3" value="247"/>
                    <count group_id="B4" value="243"/>
                    <count group_id="B5" value="244"/>
                    <count group_id="B6" value="1232"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                    <measurement group_id="B2" value="114"/>
                    <measurement group_id="B3" value="93"/>
                    <measurement group_id="B4" value="120"/>
                    <measurement group_id="B5" value="118"/>
                    <measurement group_id="B6" value="568"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="127"/>
                    <measurement group_id="B2" value="134"/>
                    <measurement group_id="B3" value="154"/>
                    <measurement group_id="B4" value="123"/>
                    <measurement group_id="B5" value="126"/>
                    <measurement group_id="B6" value="664"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Hemoglobin A1C (A1C)</title>
          <description>A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%).</description>
          <population>Participants with baseline data for A1C.</population>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="244"/>
                    <count group_id="B2" value="247"/>
                    <count group_id="B3" value="242"/>
                    <count group_id="B4" value="237"/>
                    <count group_id="B5" value="241"/>
                    <count group_id="B6" value="1211"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.6" spread="1.0"/>
                    <measurement group_id="B2" value="8.6" spread="1.0"/>
                    <measurement group_id="B3" value="8.5" spread="1.0"/>
                    <measurement group_id="B4" value="8.6" spread="1.0"/>
                    <measurement group_id="B5" value="8.6" spread="1.0"/>
                    <measurement group_id="B6" value="8.6" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Body Weight</title>
          <units>Kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="250"/>
                    <count group_id="B2" value="248"/>
                    <count group_id="B3" value="247"/>
                    <count group_id="B4" value="243"/>
                    <count group_id="B5" value="244"/>
                    <count group_id="B6" value="1232"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88.6" spread="22.2"/>
                    <measurement group_id="B2" value="88.0" spread="20.3"/>
                    <measurement group_id="B3" value="89.8" spread="23.4"/>
                    <measurement group_id="B4" value="89.5" spread="20.8"/>
                    <measurement group_id="B5" value="87.5" spread="20.5"/>
                    <measurement group_id="B6" value="88.7" spread="21.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Fasting Plasma Glucose</title>
          <description>Blood glucose was measured on a fasting basis after at least a 10-hour fast.</description>
          <population>Participants with baseline data for Fasting Plasma Glucose.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="250"/>
                    <count group_id="B2" value="247"/>
                    <count group_id="B3" value="246"/>
                    <count group_id="B4" value="240"/>
                    <count group_id="B5" value="241"/>
                    <count group_id="B6" value="1224"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="184.1" spread="52.2"/>
                    <measurement group_id="B2" value="179.5" spread="45.7"/>
                    <measurement group_id="B3" value="177.4" spread="46.6"/>
                    <measurement group_id="B4" value="183.8" spread="44.3"/>
                    <measurement group_id="B5" value="177.2" spread="49.4"/>
                    <measurement group_id="B6" value="180.4" spread="47.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Static Beta-Cell Sensitivity to Glucose Index</title>
          <description>Static beta-cell sensitivity to glucose index (SBCSGI) estimates the ratio of insulin secretion (expressed in pmol/min) related to above-basal glucose concentration (expressed in mmol/L * L) following a meal. Blood samples were collected before and after a standard meal and glucose, insulin, and C-peptide levels were analyzed. The C-peptides minimal model was used to estimate the insulin secretion rate. Analysis was performed with non-linear least squares using the Software Architecture Analysis Method (SAAM) II software. SBCSGI was expressed in units of 10^-9 min^-1.</description>
          <population>Participants with baseline data for SBCSGI.</population>
          <units>SBCSGI (10^-9min^-1)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="58"/>
                    <count group_id="B2" value="58"/>
                    <count group_id="B3" value="55"/>
                    <count group_id="B4" value="48"/>
                    <count group_id="B5" value="50"/>
                    <count group_id="B6" value="269"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.9" spread="26.1"/>
                    <measurement group_id="B2" value="18.0" spread="16.3"/>
                    <measurement group_id="B3" value="20.2" spread="21.2"/>
                    <measurement group_id="B4" value="20.0" spread="16.6"/>
                    <measurement group_id="B5" value="19.3" spread="21.0"/>
                    <measurement group_id="B6" value="19.7" spread="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sitting Systolic Blood Pressure</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="250"/>
                    <count group_id="B2" value="248"/>
                    <count group_id="B3" value="247"/>
                    <count group_id="B4" value="243"/>
                    <count group_id="B5" value="244"/>
                    <count group_id="B6" value="1232"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="129.7" spread="12.5"/>
                    <measurement group_id="B2" value="128.9" spread="12.5"/>
                    <measurement group_id="B3" value="128.3" spread="12.2"/>
                    <measurement group_id="B4" value="130.2" spread="12.6"/>
                    <measurement group_id="B5" value="129.1" spread="13.3"/>
                    <measurement group_id="B6" value="129.3" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline estimated glomerular filtration rate, eGFR</title>
          <description>eGFR is a parameter used to assess kidney function.</description>
          <population>Participants with baseline data for eGFR.</population>
          <units>mL/min/1.73m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="250"/>
                    <count group_id="B2" value="248"/>
                    <count group_id="B3" value="247"/>
                    <count group_id="B4" value="242"/>
                    <count group_id="B5" value="244"/>
                    <count group_id="B6" value="1231"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91.9" spread="20.6"/>
                    <measurement group_id="B2" value="92.8" spread="21.4"/>
                    <measurement group_id="B3" value="92.6" spread="18.2"/>
                    <measurement group_id="B4" value="91.9" spread="20.4"/>
                    <measurement group_id="B5" value="92.6" spread="19.2"/>
                    <measurement group_id="B6" value="92.4" spread="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in A1C at Week 26: Excluding Rescue Approach</title>
        <description>A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). This change from baseline reflects the Week 26 A1C minus the Week 0 A1C. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.</description>
        <time_frame>Baseline and Week 26</time_frame>
        <population>The analysis population consisted of all randomized participants who received at least one dose of study treatment, had a baseline measurement or a post-randomization measurement for the A1C change from baseline at Week 26 analysis endpoint subsequent to at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, oral, once daily for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg</title>
            <description>Ertugliflozin, oral, once daily for 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin 100 mg</title>
            <description>Sitagliptin 100 mg, oral, once daily for 52 weeks</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 5 mg + Sitagliptin 100 mg</title>
            <description>Ertugliflozin 5 mg + sitagliptin 100 mg, oral, once daily for 52 weeks</description>
          </group>
          <group group_id="O5">
            <title>Ertugliflozin 15 mg + Sitagliptin 100 mg</title>
            <description>Ertugliflozin 15 mg + sitagliptin 100 mg, oral, once daily for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in A1C at Week 26: Excluding Rescue Approach</title>
          <description>A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). This change from baseline reflects the Week 26 A1C minus the Week 0 A1C. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.</description>
          <population>The analysis population consisted of all randomized participants who received at least one dose of study treatment, had a baseline measurement or a post-randomization measurement for the A1C change from baseline at Week 26 analysis endpoint subsequent to at least one dose of study treatment.</population>
          <units>Percentage</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="250"/>
                <count group_id="O2" value="248"/>
                <count group_id="O3" value="247"/>
                <count group_id="O4" value="243"/>
                <count group_id="O5" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.02" lower_limit="-1.14" upper_limit="-0.90"/>
                    <measurement group_id="O2" value="-1.08" lower_limit="-1.20" upper_limit="-0.96"/>
                    <measurement group_id="O3" value="-1.05" lower_limit="-1.17" upper_limit="-0.93"/>
                    <measurement group_id="O4" value="-1.49" lower_limit="-1.61" upper_limit="-1.36"/>
                    <measurement group_id="O5" value="-1.52" lower_limit="-1.64" upper_limit="-1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Constrained longitudinal data analysis (cLDA) model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.</p_value_desc>
            <method>Constrained longitudinal data analysis</method>
            <param_type>Difference in the least squares means</param_type>
            <param_value>-0.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.63</ci_lower_limit>
            <ci_upper_limit>-0.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.</p_value_desc>
            <method>Constrained longitudinal data analysis</method>
            <param_type>Difference in the least squares means</param_type>
            <param_value>-0.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.60</ci_lower_limit>
            <ci_upper_limit>-0.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.</p_value_desc>
            <method>Constrained longitudinal data analysis</method>
            <param_type>Difference in the least squares means</param_type>
            <param_value>-0.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.61</ci_lower_limit>
            <ci_upper_limit>-0.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.</p_value_desc>
            <method>Constrained longitudinal data analysis</method>
            <param_type>Difference in the least squares means</param_type>
            <param_value>-0.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.63</ci_lower_limit>
            <ci_upper_limit>-0.30</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Experienced an Adverse Event (AE): Including Rescue Approach</title>
        <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Including rescue approach data analysis included data following the initiation of rescue therapy.</description>
        <time_frame>Up to 54 weeks</time_frame>
        <population>The analysis population consists of all randomized participants who received at least 1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, oral, once daily for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg</title>
            <description>Ertugliflozin, oral, once daily for 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin 100 mg</title>
            <description>Sitagliptin 100 mg, oral, once daily for 52 weeks</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 5 mg + Sitagliptin 100 mg</title>
            <description>Ertugliflozin 5 mg + sitagliptin 100 mg, oral, once daily for 52 weeks</description>
          </group>
          <group group_id="O5">
            <title>Ertugliflozin 15 mg + Sitagliptin 100 mg</title>
            <description>Ertugliflozin 15 mg + sitagliptin 100 mg, oral, once daily for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experienced an Adverse Event (AE): Including Rescue Approach</title>
          <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Including rescue approach data analysis included data following the initiation of rescue therapy.</description>
          <population>The analysis population consists of all randomized participants who received at least 1 dose of study treatment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="250"/>
                <count group_id="O2" value="248"/>
                <count group_id="O3" value="247"/>
                <count group_id="O4" value="243"/>
                <count group_id="O5" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.0"/>
                    <measurement group_id="O2" value="57.7"/>
                    <measurement group_id="O3" value="57.5"/>
                    <measurement group_id="O4" value="58.8"/>
                    <measurement group_id="O5" value="55.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in % vs Ertugliflozin 5 mg</param_type>
            <param_value>-3.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.7</ci_lower_limit>
            <ci_upper_limit>5.5</ci_upper_limit>
            <estimate_desc>Based on Miettinen &amp; Nurminen method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in % vs. Ertugliflozin 15 mg</param_type>
            <param_value>-1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.6</ci_lower_limit>
            <ci_upper_limit>6.8</ci_upper_limit>
            <estimate_desc>Based on Miettinen &amp; Nurminen method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in % vs. Sitagliptin 100 mg</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.4</ci_lower_limit>
            <ci_upper_limit>10.1</ci_upper_limit>
            <estimate_desc>Based on Miettinen &amp; Nurminen method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in % vs. Sitagliptin 100 mg</param_type>
            <param_value>-1.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.5</ci_lower_limit>
            <ci_upper_limit>7.0</ci_upper_limit>
            <estimate_desc>Based on Miettinen &amp; Nurminen method.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Discontinued Study Treatment Due to an AE: Including Rescue Approach</title>
        <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Including rescue approach data analysis included data following the initiation of rescue therapy.</description>
        <time_frame>Up to 52 weeks</time_frame>
        <population>The analysis population consists of all randomized participants who received at least 1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, oral, once daily for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg</title>
            <description>Ertugliflozin, oral, once daily for 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin 100 mg</title>
            <description>Sitagliptin 100 mg, oral, once daily for 52 weeks</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 5 mg + Sitagliptin 100 mg</title>
            <description>Ertugliflozin 5 mg + sitagliptin 100 mg, oral, once daily for 52 weeks</description>
          </group>
          <group group_id="O5">
            <title>Ertugliflozin 15 mg + Sitagliptin 100 mg</title>
            <description>Ertugliflozin 15 mg + sitagliptin 100 mg, oral, once daily for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Discontinued Study Treatment Due to an AE: Including Rescue Approach</title>
          <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Including rescue approach data analysis included data following the initiation of rescue therapy.</description>
          <population>The analysis population consists of all randomized participants who received at least 1 dose of study treatment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="250"/>
                <count group_id="O2" value="248"/>
                <count group_id="O3" value="247"/>
                <count group_id="O4" value="243"/>
                <count group_id="O5" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2"/>
                    <measurement group_id="O2" value="3.2"/>
                    <measurement group_id="O3" value="2.8"/>
                    <measurement group_id="O4" value="3.3"/>
                    <measurement group_id="O5" value="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in % vs. Ertugliflozin 5 mg</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.3</ci_lower_limit>
            <ci_upper_limit>3.6</ci_upper_limit>
            <estimate_desc>Based on Miettinen &amp; Nurminen method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in % vs. Ertugliflozin 15 mg</param_type>
            <param_value>0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.0</ci_lower_limit>
            <ci_upper_limit>4.0</ci_upper_limit>
            <estimate_desc>Based on Miettinen &amp; Nurminen method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in % vs. Sitagliptin 100 mg</param_type>
            <param_value>0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.9</ci_lower_limit>
            <ci_upper_limit>3.9</ci_upper_limit>
            <estimate_desc>Based on Miettinen &amp; Nurminen method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in % vs. Sitagliptin 100 mg</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.5</ci_lower_limit>
            <ci_upper_limit>4.4</ci_upper_limit>
            <estimate_desc>Based on Miettinen &amp; Nurminen method.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Weight at Week 26: Excluding Rescue Approach</title>
        <description>This change from baseline reflects the Week 26 body weight minus the Week 0 body weight. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.</description>
        <time_frame>Baseline and Week 26</time_frame>
        <population>The analysis population consisted of all randomized participants who received at least one dose of study treatment, had a baseline measurement or a post-randomization measurement for the body weight change from baseline at Week 26 analysis endpoint subsequent to at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, oral, once daily for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg</title>
            <description>Ertugliflozin, oral, once daily for 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin 100 mg</title>
            <description>Sitagliptin 100 mg, oral, once daily for 52 weeks</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 5 mg + Sitagliptin 100 mg</title>
            <description>Ertugliflozin 5 mg + sitagliptin 100 mg, oral, once daily for 52 weeks</description>
          </group>
          <group group_id="O5">
            <title>Ertugliflozin 15 mg + Sitagliptin 100 mg</title>
            <description>Ertugliflozin 15 mg + sitagliptin 100 mg, oral, once daily for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Weight at Week 26: Excluding Rescue Approach</title>
          <description>This change from baseline reflects the Week 26 body weight minus the Week 0 body weight. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.</description>
          <population>The analysis population consisted of all randomized participants who received at least one dose of study treatment, had a baseline measurement or a post-randomization measurement for the body weight change from baseline at Week 26 analysis endpoint subsequent to at least one dose of study treatment.</population>
          <units>Kilograms</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="250"/>
                <count group_id="O2" value="248"/>
                <count group_id="O3" value="247"/>
                <count group_id="O4" value="243"/>
                <count group_id="O5" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.69" lower_limit="-3.13" upper_limit="-2.25"/>
                    <measurement group_id="O2" value="-3.74" lower_limit="-4.18" upper_limit="-3.29"/>
                    <measurement group_id="O3" value="-0.67" lower_limit="-1.12" upper_limit="-0.22"/>
                    <measurement group_id="O4" value="-2.52" lower_limit="-2.97" upper_limit="-2.07"/>
                    <measurement group_id="O5" value="-2.94" lower_limit="-3.39" upper_limit="-2.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>cLDA model including fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.</p_value_desc>
            <method>Constrained longitudinal data analysis</method>
            <param_type>Difference in the least squares means</param_type>
            <param_value>-1.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.48</ci_lower_limit>
            <ci_upper_limit>-1.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>cLDA model including fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.</p_value_desc>
            <method>Constrained logitudinal data analysis</method>
            <param_type>Difference in the least squares means</param_type>
            <param_value>-2.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.90</ci_lower_limit>
            <ci_upper_limit>-1.64</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26 - Excluding Rescue Approach</title>
        <description>Blood glucose was measured on a fasting basis after at least a 10-hour fast. This change from baseline reflects the Week 26 FPG minus the Week 0 FPG. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.</description>
        <time_frame>Baseline and Week 26</time_frame>
        <population>The analysis population consisted of all randomized participants who received at least one dose of study treatment, had a baseline measurement or a post-randomization measurement for the FPG change from baseline at Week 26 analysis endpoint subsequent to at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, oral, once daily for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg</title>
            <description>Ertugliflozin, oral, once daily for 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin 100 mg</title>
            <description>Sitagliptin 100 mg, oral, once daily for 52 weeks</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 5 mg + Sitagliptin 100 mg</title>
            <description>Ertugliflozin 5 mg + sitagliptin 100 mg, oral, once daily for 52 weeks</description>
          </group>
          <group group_id="O5">
            <title>Ertugliflozin 15 mg + Sitagliptin 100 mg</title>
            <description>Ertugliflozin 15 mg + sitagliptin 100 mg, oral, once daily for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26 - Excluding Rescue Approach</title>
          <description>Blood glucose was measured on a fasting basis after at least a 10-hour fast. This change from baseline reflects the Week 26 FPG minus the Week 0 FPG. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.</description>
          <population>The analysis population consisted of all randomized participants who received at least one dose of study treatment, had a baseline measurement or a post-randomization measurement for the FPG change from baseline at Week 26 analysis endpoint subsequent to at least one dose of study treatment.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="250"/>
                <count group_id="O2" value="248"/>
                <count group_id="O3" value="247"/>
                <count group_id="O4" value="243"/>
                <count group_id="O5" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.73" lower_limit="-40.04" upper_limit="-31.42"/>
                    <measurement group_id="O2" value="-36.91" lower_limit="-41.21" upper_limit="-32.62"/>
                    <measurement group_id="O3" value="-25.56" lower_limit="-29.93" upper_limit="-21.19"/>
                    <measurement group_id="O4" value="-43.96" lower_limit="-48.29" upper_limit="-39.63"/>
                    <measurement group_id="O5" value="-48.70" lower_limit="-53.01" upper_limit="-44.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <p_value_desc>cLDA model including fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.</p_value_desc>
            <method>cLDA</method>
            <param_type>Difference in the least squares means</param_type>
            <param_value>-8.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.82</ci_lower_limit>
            <ci_upper_limit>-2.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>cLDA model including fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.</p_value_desc>
            <method>cLDA</method>
            <param_type>Difference in the least squares means</param_type>
            <param_value>-11.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.35</ci_lower_limit>
            <ci_upper_limit>-6.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>cLDA model including fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.</p_value_desc>
            <method>cLDA</method>
            <param_type>Difference in the least squares means</param_type>
            <param_value>-18.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.03</ci_lower_limit>
            <ci_upper_limit>-12.77</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>cLDA model including fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.</p_value_desc>
            <method>cLDA</method>
            <param_type>Difference in the least squares means</param_type>
            <param_value>-23.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-28.76</ci_lower_limit>
            <ci_upper_limit>-17.53</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving a Hemoglobin A1C of &lt;7% (&lt;53 mmol/Mol) (Raw Proportions): Excluding Rescue Approach</title>
        <description>A1C is blood marker used to report average blood glucose levels over a prolonged periods of time and is reported as a percentage (%). Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.</description>
        <time_frame>Week 26</time_frame>
        <population>The analysis population consisted of all randomized participants who received at least one dose of study treatment, had a post-randomization measurement for the A1C change from baseline at Week 26 analysis endpoint subsequent to at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, oral, once daily for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg</title>
            <description>Ertugliflozin, oral, once daily for 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin 100 mg</title>
            <description>Sitagliptin 100 mg, oral, once daily for 52 weeks</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 5 mg + Sitagliptin 100 mg</title>
            <description>Ertugliflozin 5 mg + sitagliptin 100 mg, oral, once daily for 52 weeks</description>
          </group>
          <group group_id="O5">
            <title>Ertugliflozin 15 mg + Sitagliptin 100 mg</title>
            <description>Ertugliflozin 15 mg + sitagliptin 100 mg, oral, once daily for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a Hemoglobin A1C of &lt;7% (&lt;53 mmol/Mol) (Raw Proportions): Excluding Rescue Approach</title>
          <description>A1C is blood marker used to report average blood glucose levels over a prolonged periods of time and is reported as a percentage (%). Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.</description>
          <population>The analysis population consisted of all randomized participants who received at least one dose of study treatment, had a post-randomization measurement for the A1C change from baseline at Week 26 analysis endpoint subsequent to at least one dose of study treatment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="250"/>
                <count group_id="O2" value="248"/>
                <count group_id="O3" value="247"/>
                <count group_id="O4" value="243"/>
                <count group_id="O5" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.4"/>
                    <measurement group_id="O2" value="31.9"/>
                    <measurement group_id="O3" value="32.8"/>
                    <measurement group_id="O4" value="52.3"/>
                    <measurement group_id="O5" value="49.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Adjusted Odds Ratio using a logistic regression model fitted with fixed effects for treatment, covariates for baseline A1C and baseline eGFR.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.68</ci_lower_limit>
            <ci_upper_limit>6.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Adjusted Odds Ratio using a logistic regression model fitted with fixed effects for treatment, covariates for baseline A1C and baseline eGFR.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.68</ci_lower_limit>
            <ci_upper_limit>3.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Adjusted Odds Ratio using a logistic regression model fitted with fixed effects for treatment, covariates for baseline A1C and baseline eGFR.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.92</ci_lower_limit>
            <ci_upper_limit>4.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Adjusted Odds Ratio using a logistic regression model fitted with fixed effects for treatment, covariates for baseline A1C and baseline eGFR.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.69</ci_lower_limit>
            <ci_upper_limit>3.89</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Static Beta-Cell Sensitivity to Glucose Index at Week 26; Excluding Rescue Approach</title>
        <description>Static beta-cell sensitivity to glucose index (SBCSGI) estimates the ratio of insulin secretion (expressed in pmol/min) related to above-basal glucose concentration (expressed in mmol/L * L) following a meal. Blood samples were collected before and after a standard meal and glucose, insulin, and C-peptide levels were analyzed. The C-peptides minimal model was used to estimate the insulin secretion rate (ISR). Analysis included both non-model-based [including insulinogenic index with C-peptide, glucose area under the curve (AUC)/insulin AUC] and model-based [beta cell function and insulin secretion rate at 9 mM glucose] testing. Analysis was performed with non-linear least squares using the Software Architecture Analysis Method (SAAM) II software. SBCSGI was expressed in units of 10^-9 min^-1. Excluding rescue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.</description>
        <time_frame>30 min. before and 0, 15, 30, 60, 90, 120, and 180 minutes following the start of the standard meal at Baseline and Week 26</time_frame>
        <population>The analysis population consisted of all randomized participants who received at least one dose of study treatment, had a baseline measurement or a post-randomization measurement for the beta-cell responsivity static component change from baseline at Week 26 analysis endpoint subsequent to at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, oral, once daily for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg</title>
            <description>Ertugliflozin, oral, once daily for 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin 100 mg</title>
            <description>Sitagliptin 100 mg, oral, once daily for 52 weeks</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 5 mg + Sitagliptin 100 mg</title>
            <description>Ertugliflozin 5 mg + sitagliptin 100 mg, oral, once daily for 52 weeks</description>
          </group>
          <group group_id="O5">
            <title>Ertugliflozin 15 mg + Sitagliptin 100 mg</title>
            <description>Ertugliflozin 15 mg + sitagliptin 100 mg, oral, once daily for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Static Beta-Cell Sensitivity to Glucose Index at Week 26; Excluding Rescue Approach</title>
          <description>Static beta-cell sensitivity to glucose index (SBCSGI) estimates the ratio of insulin secretion (expressed in pmol/min) related to above-basal glucose concentration (expressed in mmol/L * L) following a meal. Blood samples were collected before and after a standard meal and glucose, insulin, and C-peptide levels were analyzed. The C-peptides minimal model was used to estimate the insulin secretion rate (ISR). Analysis included both non-model-based [including insulinogenic index with C-peptide, glucose area under the curve (AUC)/insulin AUC] and model-based [beta cell function and insulin secretion rate at 9 mM glucose] testing. Analysis was performed with non-linear least squares using the Software Architecture Analysis Method (SAAM) II software. SBCSGI was expressed in units of 10^-9 min^-1. Excluding rescue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.</description>
          <population>The analysis population consisted of all randomized participants who received at least one dose of study treatment, had a baseline measurement or a post-randomization measurement for the beta-cell responsivity static component change from baseline at Week 26 analysis endpoint subsequent to at least one dose of study treatment.</population>
          <units>SBCSGI (10^-9min^-1)</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="63"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.62" lower_limit="1.28" upper_limit="15.96"/>
                    <measurement group_id="O2" value="9.71" lower_limit="2.29" upper_limit="17.13"/>
                    <measurement group_id="O3" value="21.11" lower_limit="13.55" upper_limit="28.67"/>
                    <measurement group_id="O4" value="16.24" lower_limit="8.36" upper_limit="24.11"/>
                    <measurement group_id="O5" value="11.51" lower_limit="3.76" upper_limit="19.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.155</p_value>
            <p_value_desc>cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.</p_value_desc>
            <method>Constrained longitudinal data analysis</method>
            <param_type>Difference in the least squares means</param_type>
            <param_value>7.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.90</ci_lower_limit>
            <ci_upper_limit>18.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.369</p_value>
            <p_value_desc>cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.</p_value_desc>
            <method>Constrained longitudinal data analysis</method>
            <param_type>Difference in the least squares means</param_type>
            <param_value>-4.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.54</ci_lower_limit>
            <ci_upper_limit>5.80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.734</p_value>
            <p_value_desc>cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.</p_value_desc>
            <method>Constrained longitudinal data analysis</method>
            <param_type>Difference in the least squares means</param_type>
            <param_value>1.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.66</ci_lower_limit>
            <ci_upper_limit>12.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.075</p_value>
            <p_value_desc>cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.</p_value_desc>
            <method>Difference in the least squares means</method>
            <param_type>Difference in the least squares means</param_type>
            <param_value>-9.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.17</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Sitting Systolic Blood Pressure at Week 26: Excluding Rescue Approach</title>
        <description>This change from baseline reflects the Week 26 systolic blood pressure minus the Week 0 systolic blood pressure. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.</description>
        <time_frame>Baseline and Week 26</time_frame>
        <population>The analysis population consisted of all randomized participants who received at least one dose of study treatment, had a baseline measurement or a post-randomization measurement for the systolic blood pressure change from baseline at Week 26 analysis endpoint subsequent to at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, oral, once daily for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg</title>
            <description>Ertugliflozin, oral, once daily for 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin 100 mg</title>
            <description>Sitagliptin 100 mg, oral, once daily for 52 weeks</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 5 mg + Sitagliptin 100 mg</title>
            <description>Ertugliflozin 5 mg + sitagliptin 100 mg, oral, once daily for 52 weeks</description>
          </group>
          <group group_id="O5">
            <title>Ertugliflozin 15 mg + Sitagliptin 100 mg</title>
            <description>Ertugliflozin 15 mg + sitagliptin 100 mg, oral, once daily for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Sitting Systolic Blood Pressure at Week 26: Excluding Rescue Approach</title>
          <description>This change from baseline reflects the Week 26 systolic blood pressure minus the Week 0 systolic blood pressure. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.</description>
          <population>The analysis population consisted of all randomized participants who received at least one dose of study treatment, had a baseline measurement or a post-randomization measurement for the systolic blood pressure change from baseline at Week 26 analysis endpoint subsequent to at least one dose of study treatment.</population>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="250"/>
                <count group_id="O2" value="248"/>
                <count group_id="O3" value="247"/>
                <count group_id="O4" value="243"/>
                <count group_id="O5" value="245"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.89" lower_limit="-5.28" upper_limit="-2.50"/>
                    <measurement group_id="O2" value="-3.69" lower_limit="-5.08" upper_limit="-2.30"/>
                    <measurement group_id="O3" value="-0.66" lower_limit="-2.07" upper_limit="0.76"/>
                    <measurement group_id="O4" value="-3.42" lower_limit="-4.82" upper_limit="-2.03"/>
                    <measurement group_id="O5" value="-3.67" lower_limit="-5.06" upper_limit="-2.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <p_value_desc>cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.</p_value_desc>
            <method>Constrained longitudinal data analysis</method>
            <param_type>Difference in the least squares means</param_type>
            <param_value>-2.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.69</ci_lower_limit>
            <ci_upper_limit>-0.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.</p_value_desc>
            <method>Constrained longitudinal data analysis</method>
            <param_type>Difference in the least squares means</param_type>
            <param_value>-3.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.94</ci_lower_limit>
            <ci_upper_limit>-1.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 54 weeks</time_frame>
      <desc>The safety population consisted of all randomized participants who took at least one dose of trial treatment. Participants were included in the treatment group corresponding to the trial treatment they actually took. This analysis included events that occurred following the initiation of rescue therapy.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ertugliflozin 5 mg</title>
          <description>Ertugliflozin 5 mg, oral, once daily for 52 weeks</description>
        </group>
        <group group_id="E2">
          <title>Ertugliflozin 15 mg</title>
          <description>Ertugliflozin, oral, once daily for 52 weeks</description>
        </group>
        <group group_id="E3">
          <title>Sitagliptin 100 mg</title>
          <description>Sitagliptin 100 mg, oral, once daily for 52 weeks</description>
        </group>
        <group group_id="E4">
          <title>Ertugliflozin 5 mg + Sitagliptin 100 mg</title>
          <description>Ertugliflozin 5 mg + sitagliptin 100 mg, oral, once daily for 52 weeks</description>
        </group>
        <group group_id="E5">
          <title>Ertugliflozin 15 mg + Sitagliptin 100 mg</title>
          <description>Ertugliflozin 15 mg + sitagliptin 100 mg, oral, once daily for 52 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="248"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="243"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Microvascular coronary artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Femoral hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Cellulitis orbital</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Gastroenteritis norovirus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Pneumococcal sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Blood sodium decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Nodal marginal zone B-cell lymphoma stage III</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Pancreatic neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="248"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="248"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="243"/>
                <counts group_id="E5" subjects_affected="38" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="250"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="248"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="247"/>
                <counts group_id="E4" events="14" subjects_affected="12" subjects_at_risk="243"/>
                <counts group_id="E5" events="13" subjects_affected="12" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="24" subjects_affected="20" subjects_at_risk="250"/>
                <counts group_id="E2" events="23" subjects_affected="19" subjects_at_risk="248"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="247"/>
                <counts group_id="E4" events="18" subjects_affected="14" subjects_at_risk="243"/>
                <counts group_id="E5" events="12" subjects_affected="8" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="25" subjects_affected="12" subjects_at_risk="250"/>
                <counts group_id="E2" events="29" subjects_affected="13" subjects_at_risk="248"/>
                <counts group_id="E3" events="22" subjects_affected="11" subjects_at_risk="247"/>
                <counts group_id="E4" events="17" subjects_affected="9" subjects_at_risk="243"/>
                <counts group_id="E5" events="42" subjects_affected="20" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

